肾癌患者外周血sTNFR-Ⅱ、sCD163预测切缘阳性的价值-东南大学学报医学版

肾癌患者外周血sTNFR-Ⅱ、sCD163预测切缘阳性的价值

单位：新疆医科大学附属中医医院泌尿外科, 新疆乌鲁木齐 830000

分类号：R737.11

出版年·卷·期（页码）：2023·42·第三期（377-384）

摘要：

目的: 分析肾癌患者外周血可溶性肿瘤坏死因子受体Ⅱ(sTNFR-Ⅱ)、可溶性CD163(sCD163)预测切缘阳性的价值。方法: 选取我院肾癌患者324例,同期健康体检者108例。Logistic回归分析患者术后切缘阳性的影响因素,应用相加模型评估血清sTNFR-Ⅱ、sCD163对肾癌患者术后切缘阳性的交互作用,并采用受试者工作特征(ROC)曲线分析血清sTNFR-Ⅱ、sCD163预测肾癌患者术后切缘阳性的价值。结果: 肾癌患者血清sTNFR-Ⅱ、sCD163水平高于健康体检者(P＜0.05);324例患者术后切缘阳性37例,切缘阴性287例,切缘阳性率为11.42%;血清sTNFR-Ⅱ、sCD163水平是肾癌患者术后切缘阳性的影响因素(P＜0.05);血清sTNFR-Ⅱ、sCD163对患者术后切缘阳性存在协同作用,协同效应为二者单独存在产生效应之和的1.375倍(协同指数=1.375);血清sTNFR-Ⅱ水平＞A、sCD163水平＞B时肾癌患者术后切缘阳性风险较高,其AUC值分别为0.739、0.826,二者联合检测的AUC值为0.860。结论: 肾癌患者血清sTNFR-Ⅱ、sCD163水平明显升高,二者对肾癌患者术后切缘阳性存在协同作用,其中血清sTNFR-Ⅱ＞3.26 μg·L^-1、sCD163＞66.90 mg·ml^-1时提示患者术后切缘阳性风险较高。

Objective: To analyze the predictive values of soluble tumor necrosis factor receptor Ⅱ(sTNFRⅡ) and soluble CD163(sCD163) in peripheral blood of patients with renal cancer. Methods: A total of 324 patients with renal cancer in our hospital were selected, and 108 healthy subjects during the same period were selected. Logistic regression analysis was used to analyze the influencing factors of postoperative positive surgical margins. An additive model was used to evaluate the interaction of serum sTNFR-Ⅱ and sCD163 on positive postoperative margins in patients with renal cancer. The receiver operating characteristic(ROC) curve was used to analyze the values of serum sTNFR-Ⅱ and sCD163 in predicting the positive postoperative margins of renal cancer patients. Results: The serum levels of sTNFR-Ⅱ and sCD163 in patients with renal cancer were higher than those in healthy people(P<0.05).Of the 324 patients, 37 had positive margins and 287 had negative margins, with a positive rate of 11.42%. The levels of serum sTNFR-Ⅱ and sCD163 were the influencing factors of positive postoperative margins in patients with renal cancer(P＜0.05).Serum sTNFR-Ⅱ and sCD163 had a synergistic effect on the positive postoperative margin of patients, and the synergistic effect was 1.375 times the sum of the effects of the two alone(SI=1.375).When serum sTNFR-Ⅱ level>A, sCD163 level>B, renal cancer patients had a higher risk of positive postoperative margins, and their AUC values were 0.739 and 0.826, respectively, and AUC of combination detection was 0.860. Conclusion: The serum levels of sTNFR-Ⅱ and sCD163 in renal cancer patients are significantly increased, and the two have a synergistic effect on the positive postoperative margins of renal cancer patients. Among them, serum sTNFR-Ⅱ>3.26 μg·L^-1 and sCD163>66.90 mg·ml^-1 indicate that patients have a higher risk of positive postoperative margins.

参考文献：

[1] LEE H J,SHIN D H,NOH G Y,et al.Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods[J].Oncotarget,2017,8(19):30756-30765.
[2] BERTOLO R,AUTORINO R,FIORI C,et al.Expanding the indications of robotic partial nephrectomy for highly complex renal tumors: urologists' perception of the impact of hyperaccuracy three-dimensional reconstruction[J].J LaparoendoscAdvSurg Tech A,2019,29(2):233-239.
[3] LONG J A,BERNHARD J C,BIGOT P,et al.Partial nephrectomy versus ablative therapy for the treatment of renal tumors in an imperative setting[J].World J Urol,2017,35(4):649-656.
[4] MIR M C,DERWEESH I,PORPIGLIA F,et al.Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies[J].Eur Urol,2017,71(4):606-617.
[5] CAI Y,LI H Z, ZHANG Y S.Comparison of partial and radical laparascopic nephrectomy: long-term outcomes for clinical T1b renal cell carcinoma[J].Urol J,2018,15(2):16-20.
[6] KIM H,KIM J K,YE C,et al.Recurrence after radical and partial nephrectomy in high complex renal tumor using propensity score matched analysis[J].Sci Rep,2021,11(1):2919.
[7] PETROS F G,METCALFE M J,YU K J,et al.Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience[J].World J Urol,2018,36(7):1093-1101.
[8] WANG Z,YIN Y,WANG J,et al.Standardized incidence rate, risk and survival outcomes of second primary malignancy among renal cell carcinoma survivors: a nested case-control study[J].Front Oncol,2021,11(1):716741.
[9] ALKAZEMI M H,DIONISE Z R,JIANG R,et al.Partial and radical nephrectomy in children, adolescents, and young adults: Equivalent readmissions and postoperative complications[J].J Pediatr Surg,2019,54(11):2343-2347.
[10] 曾胜,白志杰,李哲,等.肾部分切除术切缘阳性对患者复发和转移影响的荟萃分析[J].中华泌尿外科杂志,2019,40(10):774-779.
[11] LENDEZ P A,MARTINEZ-CUESTA L,NIETO FARIAS M V,et al.Cytokine TNF-α and its receptors TNFRI and TNFRII play a key role in the in vitro proliferative response of BLV infected animals[J].Vet Res Commun,2021,45(4):431-439.
[12] ZHAO Y,YANG X,LI S,et al.sTNFRII-Fc modification protects human UC-MSCs against apoptosis/autophagy induced by TNF-α and enhances their efficacy in alleviating inflammatory arthritis[J].Stem Cell Res Ther,2021,12(1):535.
[13] 孔红娜,赵晓蕊,赵放,等.不同分期肾癌患者手术前后外周血干扰素-γ、IL-6和肿瘤坏死因子-α含量的变化及临床意义[J].中国实用医刊,2020,47(8):20-23.
[14] 沈瑶,周琰.血清sTNFR-Ⅱ、FGF-21和sCD163水平在早期妊娠期糖尿病肾病的临床价值[J].检验医学与临床,2021,18(13):1890-1893,1898.
[15] 周凤婷,姜兰斌,黄萍.狼疮性肾炎患者血清sCD163、sCD134的表达及与疾病活动度的相关性研究[J].河北医药,2019,41(24):3734-3737.
[16] 杨雷,李加兵,陈代,等.术前外周血炎症指标对肾癌预后价值的评估[J].现代泌尿外科杂志,2021,26(7):587-591.
[17] RYAN S.Serum sCD163 as a biomarker of adipose tissue inflammation in obstructive sleep apnoea patients: limits and perspectives[J].Eur Respir J,2017,50(2):1701182.
[18] 寇朴怀,苗建玲.血清sCD14、sCD163水平与冠状动脉粥样硬化病变程度及稳定性的相关性[J].海南医学,2021,32(15):1915-1918.
[19] ZHANG T,LI H,VANARSA K,et al.Association of urine sCD163 with proliferative lupus nephritis, fibrinoid necrosis, cellular crescents and intrarenal M2 macrophages[J].Front Immunol,2020,11(1):671.
[20] SHERMAN K E,MEEDS H L,ROUSTER S D,et al.Soluble CD163 identifies those at risk for increased hepatic inflammation & fibrosis[J].Open Forum Infect Dis,2021,8(6):ofab203.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录